The Health Ministry panel committee approve the usage of the single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately-ill COVID-19 patients. (The Japan Times) COVID-19 pandemic in Japan, COVID-19 drug developmentCOVID-19 pandemic in AsiaCOVID-19 pandemic link embed save